These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 7920871)

  • 1. Reduced growth hormone response to L-dopa and pyridostigmine in obesity.
    Lee EJ; Kim KR; Lee KM; Lim SK; Lee HC; Lee JH; Lee DJ; Huh KB
    Int J Obes Relat Metab Disord; 1994 Jul; 18(7):465-8. PubMed ID: 7920871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impaired growth hormone secretion in obese subjects is partially reversed by acipimox-mediated plasma free fatty acid depression.
    Cordido F; Peino R; Peñalva A; Alvarez CV; Casanueva FF; Dieguez C
    J Clin Endocrinol Metab; 1996 Mar; 81(3):914-8. PubMed ID: 8772550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acipimox potentiates growth hormone (GH) response to GH-releasing hormone with or without pyridostigmine by lowering serum free fatty acid in normal and obese subjects.
    Lee EJ; Nam SY; Kim KR; Lee HC; Cho JH; Nam MS; Song YD; Lim SK; Huh KB
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2495-8. PubMed ID: 7629249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth hormone response to L-dopa and pyridostigmine in women with polycystic ovarian syndrome.
    Lee EJ; Lee BS; Lee HC; Park KH; Song CH; Huh KB
    Fertil Steril; 1993 Jul; 60(1):53-7. PubMed ID: 8513959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acipimox-mediated plasma free fatty acid depression per se stimulates growth hormone (GH) secretion in normal subjects and potentiates the response to other GH-releasing stimuli.
    Peino R; Cordido F; Peñalva A; Alvarez CV; Dieguez C; Casanueva FF
    J Clin Endocrinol Metab; 1996 Mar; 81(3):909-13. PubMed ID: 8772549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Restoration of growth hormone (GH) response to GH-releasing hormone in elderly and obese subjects by acute pharmacological reduction of plasma free fatty acids.
    Pontiroli AE; Manzoni MF; Malighetti ME; Lanzi R
    J Clin Endocrinol Metab; 1996 Nov; 81(11):3998-4001. PubMed ID: 8923850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of central cholinergic neurotransmission enhancement by pyridostigmine on the growth hormone secretion elicited by clonidine, arginine, or hypoglycemia in normal and obese subjects.
    Cordido F; Dieguez C; Casanueva FF
    J Clin Endocrinol Metab; 1990 May; 70(5):1361-70. PubMed ID: 2159483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of 36 hour fasting on GH/IGF-I axis and metabolic parameters in patients with simple obesity. Comparison with normal subjects and hypopituitary patients with severe GH deficiency.
    Maccario M; Aimaretti G; Grottoli S; Gauna C; Tassone F; Corneli G; Rossetto R; Wu Z; Strasburger CJ; Ghigo E
    Int J Obes Relat Metab Disord; 2001 Aug; 25(8):1233-9. PubMed ID: 11477509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of arginine and pyridostigmine on the GHRH-induced GH rise in obesity and Cushing's syndrome.
    Procopio M; Invitti C; Maccario M; Grottoli S; Cavagnini F; Camanni F; Ghigo E
    Int J Obes Relat Metab Disord; 1995 Feb; 19(2):108-12. PubMed ID: 7735336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term administration of acipimox potentiates growth hormone response to growth hormone-releasing hormone by decreasing serum free fatty acid in obesity.
    Nam SY; Lee ; Kim KR; Lee HC; Nam MS; Cho JH; Huh KB
    Metabolism; 1996 May; 45(5):594-7. PubMed ID: 8622602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated insulin levels contribute to the reduced growth hormone (GH) response to GH-releasing hormone in obese subjects.
    Lanzi R; Luzi L; Caumo A; Andreotti AC; Manzoni MF; Malighetti ME; Sereni LP; Pontiroli AE
    Metabolism; 1999 Sep; 48(9):1152-6. PubMed ID: 10484056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pyridostigmine enhances, but does not normalise, the GH response to GH-releasing hormone in obese subjects.
    Castro RC; Vieira JG; Chacra AR; Besser GM; Grossman AB; Lengyel AM
    Acta Endocrinol (Copenh); 1990 Mar; 122(3):385-90. PubMed ID: 2109445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic and endocrine consequences of acute suppression of FFAs by acipimox in polycystic ovary syndrome.
    Ciampelli M; Muzj G; Leoni F; Romualdi D; Belosi C; Cento RM; Lanzone A
    J Clin Endocrinol Metab; 2001 Nov; 86(11):5324-9. PubMed ID: 11701699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of l-dopa on growth hormone, glucose, insulin, and cortisol response in obese subjects.
    Vizner B; Reiner Z; Sekso M
    Exp Clin Endocrinol; 1983 Jan; 81(1):41-8. PubMed ID: 6343098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blunted GH response to growth hormone-releasing hormone (GHRH) alone or combined with arginine in non-insulin-dependent diabetes mellitus.
    Martina V; Bruno G; Tagliabue M; Bertaina S; Maccario M; Grottoli S; Procopio M; Ozzello A; Camanni F
    Horm Metab Res; 1995 Jan; 27(1):26-30. PubMed ID: 7729789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose growth hormone treatment with diet restriction accelerates body fat loss, exerts anabolic effect and improves growth hormone secretory dysfunction in obese adults.
    Kim KR; Nam SY; Song YD; Lim SK; Lee HC; Huh KB
    Horm Res; 1999; 51(2):78-84. PubMed ID: 10352397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth hormone secretion in aging. Effect of pyridostigmine on growth hormone responsiveness to growth hormone-releasing hormone.
    Giusti M; Marini G; Sessarego P; Peluffo F; Valenti S; Caratti C; Giordano G
    Recenti Prog Med; 1991 Dec; 82(12):665-8. PubMed ID: 1815302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pyridostigmine counteracts the blunted growth hormone response to growth hormone-releasing hormone of obese children.
    Loche S; Pintor C; Cappa M; Ghigo E; Puggioni R; Locatelli V; Müller EE
    Acta Endocrinol (Copenh); 1989 May; 120(5):624-8. PubMed ID: 2499149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Corticosteroid-induced growth hormone secretion in normal and obese subjects.
    Muruais C; Cordido F; Morales MJ; Casanueva FF; Diéguez C
    Clin Endocrinol (Oxf); 1991 Dec; 35(6):485-90. PubMed ID: 1769129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Very-low-calorie diet-induced weight reduction reverses impaired growth hormone secretion response to growth hormone-releasing hormone, arginine, and L-dopa in obesity.
    Tanaka K; Inoue S; Numata K; Okazaki H; Nakamura S; Takamura Y
    Metabolism; 1990 Sep; 39(9):892-6. PubMed ID: 2118219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.